


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華控康泰集團有限公司

Kontafarma China Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

**DELAY IN DESPATCH OF CIRCULAR
IN RELATION TO
A MAJOR TRANSACTION**

Reference is made to the announcement of Kontafarma China Holdings Limited (the “**Company**”) dated 13 April 2023 in relation to the disposal of an indirect non-wholly owned subsidiary of the Company (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

As stated in the Announcement, a circular (the “**Circular**”) containing, among other things, (i) a letter from the Board containing further information of the Equity Transfer Agreement and the transaction contemplated thereunder; and (ii) other information required to be included therein under the Listing Rules, was expected to be despatched to the Shareholders on or before 5 May 2023.

As additional time is required to finalise the financial information to be included in the Circular, the Company is applying to the Stock Exchange for a waiver from strict compliance with the requirements of Rule 14.41(a) of the Listing Rules and it is currently expected that the despatch date of the Circular will be postponed to a date on or before 31 May 2023.

By order of the Board of
Kontafarma China Holdings Limited
Bai Pingyan
Chairman

Hong Kong, 5 May 2023

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Bai Pingyan (Chairman), Mr. Chai Hongjie, Mr. Huang Yu (President) and Mr. Jiang Chaowen (Chief Executive Officer); and three independent non-executive Directors, namely Mr. Chan Sze Chung, Mr. Zhang Ruibin and Mr. Zhang Junxi Jack.